G+FLAS Life Sciences

Private

Last Round

Series C

Sep 3, 2019

Total Funding Raised

$28M

Company Overview

G+FLAS Life Sciences is a biotechnology company that develops new drugs, biopharmaceuticals, and novel seeds based on CRISPR gene editing technology.

Historical view of private secondary pricing and transaction trends.

Proprietary index based on bid/ask volume and sentiment.

Track how buyer interest and sentiment changes over time.

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

Access detailed peer comparisons, multiples, and valuation benchmarks.

Historical fundraising activity

Notable investors and investment history

Structured signals derived from secondary market and firmographic data.

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SEC and related filings with document metadata.

Common questions about G+FLAS Life Sciences's valuation, stock price, and market status.

HeadquartersSouth Korea

Employee Range8

Year Founded2016

Last FundingSep 3, 2019

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.